Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from

Takayuki Ikezoe1, Asako Takeuchi, Mayuka Isaka

  • 1Department of Hematology and Respiratory Medicine, Kochi University, Nankoku, Kochi, Japan. ikezoet@kochi-u.ac.jp

Leukemia Research
|August 25, 2012
PubMed

We treated individuals for disseminated intravascular coagulation (DIC) caused by acute promyelocytic leukemia (APL) (n=9) using human soluble thrombomodulin (rTM) in combination with all-trans retinoic acid (ATRA) and chemotherapy, and compared the clinical outcomes with historical control patients (n=8) treated with ATRA and/or chemotherapy. Two control patients developed intracranial vascular incidents. On the other hand, no bleeding related mortality was noted in rTM-treated patients. Notably, treatment with rTM rescued patients from DIC earlier than historical controls (log rank test, p=0.019). These results suggest that administration of rTM should be considered for the treatment of individuals with DIC associated with APL.